leptomeningeal metastasis of malignant solid tumors
Conditions
Interventions
Study group:concurrently radiotherapy and intrathecal chemothe
Sponsors
First Hospital of Jilin University Department of Radiation Oncology
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Patients who have been definitely diagnosed as leptomeningeal metastasis according to CSF cytology or neuroimaging, or patients who got the clinical diagnosis by combining with the history of cancer, clinical manifestation, CSF examination, neuroimaging etc.; 2) Patients who have been diagnosed as malignant solid tumor with definite pathologic type, excluding hematological malignancies (e.g., leukemia and lymphoma) or primary brain tumors; 3) Patients who have at least one poor prognosis factor, including low KPS, severe and diverse neurological dysfunction, encephalopathy, uncontrolled extracranial lesions without effective treatment, and the presence of brain parenchymal metastasis; 4) Male and female patients aged between 18 and 75 years; 5) No severe abnormal liver and kidney function; WBC more than 2.5*10^12, Plt more than 60*10^9; 6) No other severe chronic diseases; 7) No history of severe nervous system disease; 8) No severe dyscrasia.
Exclusion criteria
Exclusion criteria: 1) Patients with leptomeningeal metastasis from unknown primary tumor; 2) Patients who had received radiotherapy to the brain in the past 6 months; 3) Patients who had accepted systemic chemotherapy within one month before the treatment, or molecular targeted therapy less than 3 months; 4) Patients with poor compliance, or for other reasons, the researchers considered unsuitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| improving the disease related symptoms;The ratio of severe adverse events.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactLihua Dong
Outcome results
None listed